HAVCR2 and lung cancer: Preliminary signs of clinical efficacy have also been observed in patients with solid tumors, including NSCLC, who received sabatolimab and anti-PD-1 antibody spartalizumab, suggesting that blockade of TIM-3 might represent a potential therapeutic strategy in lung cancer (116).